Skip to main content
SpringerLink
Log in

Anakinra/rituximab

Altered immune response, prolongation of COVID-19 and lack of efficacy: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Notz Q, et al. Antirheumatic drugs, et al. cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian et al. Annals of the Rheumatic Diseases 81: No. 11, Nov 2022. Available from: URL: http://doi.org/10.1136/annrheumdis-2020-218778

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anakinra/rituximab. Reactions Weekly 1953, 29 (2023). https://doi.org/10.1007/s40278-023-37464-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-37464-4

Search

Navigation